Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
8 October 2021 |
Main ID: |
EUCTR2005-005047-26-FR |
Date of registration:
|
13/11/2007 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A phase III multi-center, open-label, randomized study of nilotinib versus imatinib in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML - CP) who have suboptimal cytogenetic response (CyR) on imatinib. - CAMN107A2302
|
Scientific title:
|
A phase III multi-center, open-label, randomized study of nilotinib versus imatinib in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML - CP) who have suboptimal cytogenetic response (CyR) on imatinib. - CAMN107A2302 |
Date of first enrolment:
|
26/05/2008 |
Target sample size:
|
608 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005047-26 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: yes Single blind: no Double blind: no Parallel group: yes Cross over: yes Other: no If controlled, specify comparator, Other Medicinial Product: yes Placebo: no Other: yes Other specify the comparator: Imatinib mesylate (Glivec®)
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Belgium
|
Czech Republic
|
France
|
Germany
|
Greece
|
Hungary
|
Italy
|
Netherlands
|
Spain
| | | | | | | |
Contacts
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: Male and female patients = 18 years of age. ECOG performance status of 0,1, or 2. Diagnosis of Ph+ CML-CP defined as: <15% blasts in peripheral blood and bone marrow, < 30% blasts plus promyelocytes in peripheral blood and bone marrow < 20% basophils in the peripheral blood =100 x 109 /L (>/ 100,000 /mm3) platelets No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly Patients with suboptimal cytogenetic response to a dose of 400 mg imatinib (1st line therapy) defined as = 6 to < 12 months of treatment and have 36 - 95% Ph+ metaphases, or = 12 to < 18 months of treatment and have 1 - 35% Ph+ metaphases. Bone marrow karyotyping is rquired on a min. of 20 metaphases. FISh analysis is not allowed. The following laboratory results must be present: Total bilirubin <1.5XULN; SGOT and SGPT <2.5XULN; Creatinine < 1.5XULN, Serum potassium, phosphorus, magnesium and calcium = LLN or correctable with supplements prior to the first doese of study drug. Serum amylase and lipase = 1.5xULN, alkaline phosphatase = 2.5XULN unless considered tumor related.
Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria: Prior accelerated phase or blast phase CML. Previously documented T315I mutation. Achieved prior PCyR or CCyR on imatinib and lost that response prior to entering the study. • Prior treatment with > 400 mg/day of imatinib. • Patients who have received more than 18 months of imatinib therapy. • Intolerance to imatinib = 400 mg/day defined as the inability to maintain dosing of 400 mg daily for the previous 3 months. • Previous treatment with any other tyrosine kinase inhibitor except imatinib. • Patients who had any other treatment for CML (e.g. interferon, transplant) except hydroxyurea and/or anagrelide. •Impaired cardiac function including any one of the following: • LVEF < 45% by echocardiography • Complete left bundle branch block • Congenital long QT syndrome or family history of long QT syndrome • History of or presence of significant ventricular or atrial tachyarrhythmias • Clinically significant resting brachycardia (<50 bpm) • QTcF > 450 msec on screening ECG (using the QTcF formula). If QTc > 450 and electrolytes are not with normal ranges, electrolytes should be corrected and then the patient rescreened for QTc • Use of a ventricular-paced pacemaker • Myocardial infarction within one year of the first dose of study drug • Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, unstable angina). • Treatment with strong inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbitol, St John’s Wort), and the treatment cannot be discontinued or switched to a different medication prior to starting study drug. See link in Section 6.6.4 for complete list of these medications. • Treatment with strong CYP3A4 inhibitors (e.g., erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil) and the treatment cannot be discontinued or switched to a different medication prior to starting study drug. See link in Section 6.6.4 for complete list of these medications. • Treatment with medications that have been well documented to prolong the QT interval is contraindicated. See Section 6.6.4 for further guidance. • Impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection or gastric bypass surgery). • History of acute pancreatitis within one year of study entry or medical history of chronic pancreatitis. • Known cytopathologically confirmed CNS infiltration (in absence of suspicion of CNS involvement, lumbar puncture not required). • Any other malignancy that is clinically significant or requires active intervention. • Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or chronic liver disease, pancreatic, or severe renal disease unrelated to tumor, active or uncontrolled infection). • History of significant congenital or acquired bleeding disorder unrelated to cancer. • Previous radiotherapy to = 25% of the bone marrow. • Patients who have had major surgery within 4 weeks prior to the first dose of study drug or who have not recovered from prior surgery. • Use of therapeutic coumarin derivatives (i.e. warfarin, acenocoumarol, phenprocoumon). • Treatment with other investigational agents within 28 days of Day 0 (first dose of study drug). • History of non-compliance to medical regimens or inability to grant consent. • Wo
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Nilotinib will be evaluated in patients having showed a suboptimal cytogenetic response to imatinib MedDRA version: 9.1
Level: LLT
Classification code 10009700
Term: CML
|
Intervention(s)
|
Product Name: nilotinib Product Code: AMN107 Pharmaceutical Form: Capsule, hard INN or Proposed INN: nilotinib CAS Number: 641571-10-0 Current Sponsor code: AMN107 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200-
Trade Name: Glivec Product Name: Glivec Product Code: STI571 Pharmaceutical Form: Tablet INN or Proposed INN: Imatinib, mesilate salt CAS Number: 220127-57-1 Current Sponsor code: STI571 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-
Trade Name: Glivec Product Name: Glivec Product Code: STI571 Pharmaceutical Form: Tablet INN or Proposed INN: Imatinib, mesilate salt CAS Number: 220127-57-1 Current Sponsor code: STI571 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400-
|
Primary Outcome(s)
|
Primary end point(s): Primary efficacy Complete cytogenetic Response (CCyR) rate at 12 months (CCyR is defined as 0% Ph+ metaphases)
|
Secondary Objective: •To evaluate the rate of durable CCyR at 24 mts (patients who have achieved CCyR by 12 mts, and maintain continuous CCyR until the 24 mts timepoint).
•To evaluate the rate of major molecular response (MMR) of nilotinib vs. Imatinib*. •To evaluate the rate of durable CCyR over the initial 24 mts of this study*. •To evaluate the CCyR rate of nilotinib vs. imatinib* at 24 mts. •To evaluate the time to and duration of CCyR of nilotinib vs. imatinib*. •To evaluate the time to, rate of, and duration of a = 4 log reduction in BCR-ABL transcript levels a from the standardized baseline (as established in the IRIS study), or = 0.01% BCR-ABL/control gene% by international scale of nilotinib vs. imatinib*. •To evaluate the time to and duration of MMR of nilotinib vs. imatinib*. •To describe overall survival, progression free survival and event-free survival up to 5 years*. •To evaluate the safety profile of nilotinib and vs. imatinib*.
*in adult patients with Ph+ CML in CP
|
Main Objective: To evaluate the complete cytogenetic response (CCyR) rate at 12 months of nilotinib compared to imatinib in adult patients with Ph+ CML in CP who have a suboptimal cytogenetic response to imatinib.
|
Secondary ID(s)
|
CAMN107A2302
|
2005-005047-26-BE
|
Source(s) of Monetary Support
|
Ethics review
|
Status: Approved
Approval date: 11/12/2007
Contact:
|
|